| Literature DB >> 35862046 |
Heitor Cabral Frade1, Susan E Wilson2, Anne Beckwith2, William J Powers2.
Abstract
Importance: Patients with acute ischemic stroke often undergo magnetic resonance imaging (MRI) in addition to computed tomography (CT), but its association with clinical outcomes is uncertain. Objective: To assess whether clinical outcomes of patients with acute ischemic stroke with initial CT alone were noninferior to those with additional MRI. Design, Setting, and Participants: A retrospective observational propensity score-matched cohort study of clinical outcomes at discharge and 1 year for patients hospitalized with acute ischemic stroke was conducted at an academic medical center between January 2015 and December 2017. Data collection from an electronic medical record system performed from May 2020 through January 2022 was not completely blinded. Noninferiority margins were based on the designs of previous randomized clinical trials of ischemic stroke treatments. Statistical analysis was performed in January 2022. Participants were adults hospitalized with acute ischemic stroke with admission diagnosis based on CT. Exclusion criteria were primarily missing data. From 508 eligible patients, all 123 cases with additional MRI were propensity-score matched to 123 controls without. Exposure: MRI after initial diagnosis. Main Outcomes and Measures: Death or dependence at hospital discharge (modified Rankin Scale score of 3-6) and stroke or death occurring in survivors within 1 year after discharge.Entities:
Mesh:
Year: 2022 PMID: 35862046 PMCID: PMC9305377 DOI: 10.1001/jamanetworkopen.2022.19416
Source DB: PubMed Journal: JAMA Netw Open ISSN: 2574-3805
Patient Characteristics of All Included Patients
| Variable | No. (%) | 95% CI | SMD | ||
|---|---|---|---|---|---|
| Patients who underwent MRI (n = 123) | Patients who did not undergo MRI (n = 385) | ||||
| Age, median (IQR), y | 68.4 (58-78.8) | 69.4 (59.9-81) | −4.9 to 1.2 | .24 | 0.142 |
| Sex | |||||
| Male | 65 (52.8) | 220 (57.1) | −14.4 to 5.8 | .40 | 0.086 |
| Female | 58 (47.2) | 165 (42.9) | −5.8 to 14.4 | ||
| LKN to admission, median (IQR), h | 7 (3-13) | 4.1 (2.5-6.3) | 1.3 to 3.4 | <.001 | 0.280 |
| Admission NIHSS, median (IQR) | 5 (3-10.5) | 8 (4-17) | 3 to 1 | <.001 | 0.362 |
| Baseline mRS, median (IQR) | 0 (0-1) | 0 (0-1) | 0 to 0 | .60 | 0.037 |
| Admission serum glucose level, median (IQR), mg/dL | 118 (98-148) | 118 (100-152) | −7 to 6 | .66 | 0.058 |
| Hypertension | 92 (74.8) | 299 (77.7) | −11.6 to 5.9 | .51 | 0.067 |
| Hyperlipidemia | 63 (51.2) | 195 (50.6) | −9.6 to 10.7 | .91 | 0.011 |
| Diabetes | 39 (31.7) | 119 (30.9) | −8.6 to 10.2 | .87 | 0.017 |
| Coronary disease | 17 (13.8) | 92 (23.9) | −17.5 to −2.6 | .02 | 0.259 |
| Previous myocardial infarction | 7 (5.7) | 32 (8.3) | −7.6 to 2.3 | .34 | 0.103 |
| Atrial fibrillation | 19 (15.4) | 110 (28.6) | −20.9 to −5.3 | .004 | 0.320 |
| Heart failure | 3 (2.4) | 50 (13) | −14.9 to −6.2 | .001 | 0.403 |
| Peripheral artery disease | 11 (8.9) | 33 (8.6) | −5.4 to 6.1 | .90 | 0.013 |
| Chronic kidney disease | 12 (9.0) | 29 (7.5) | −3.6 to 8.1 | .43 | 0.079 |
| Obstructive sleep apnea | 6 (4.9) | 25 (6.5) | −6.1 to 2.9 | .52 | 0.070 |
| Previous stroke | 35 (28.5) | 91 (23.6) | −4.2 to 13.9 | .28 | 0.110 |
| Previous TIA | 6 (4.9) | 27 (7) | −6.7 to 2.4 | .40 | 0.090 |
| BMI, median (IQR) | 28.4 (24.4-32.6) | 27.7 (23.7-32.1) | −0.5 to 2 | .23 | 0.168 |
| Malignant neoplasm | 20 (16.3) | 52 (13.5) | −4.6 to 10.1 | .47 | 0.077 |
| Current smoking | 28 (22.8) | 89 (23.1) | −8.9 to 8.2 | .94 | 0.008 |
| Statin pretreatment | 54 (43.9) | 199 (43.1) | −9.3 to 10.9 | .88 | 0.016 |
| CCI, median (IQR) | 4 (2-5) | 4 (2-6) | −1 to 0 | .37 | 0.115 |
| CT with acute ischemic changes | 24 (19.5) | 120 (31.2) | −20.1 to −3.3 | .01 | 0.270 |
| Intravenous thrombolysis | 35 (28.5) | 229 (59) | −39.9 to −21.1 | <.001 | 0.645 |
| Endovascular treatment | 8 (6.5) | 89 (23.1) | −22.7 to −10.6 | <.001 | 0.480 |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CCI, Charlson Comorbidity Index; CT, computed tomography; LKN, last known normal; MRI, magnetic resonance imaging; mRS, modified Rankin Scale score; NIHSS, NIH Stroke Scale; SMD, standardized mean difference; TIA, transient ischemic attack.
SI conversion factor: To convert serum glucose to millimoles per liter, multiply by 0.0555.
The 95% CI for the difference between medians or percentages subtracting patients who did not undergo MRI from patients who underwent MRI.
Figure. Participant Flow Diagram
AIS indicates acute ischemic stroke; CT, computed tomography; MRI, magnetic resonance imaging; mRS, modified Rankin Scale score; NIHSS; National Institutes of Health Stroke Scale.
Patient Characteristics of the Propensity Score–Matched Cohorts
| Variable | No. (%) | 95% CI | SMD | ||
|---|---|---|---|---|---|
| Patients who underwent MRI (n = 123) | Patients who did not undergo MRI (n = 123) | ||||
| Age, median (IQR), y | 68.4 (58-78.8) | 68 (58.2-79.1) | −3.7 to 3.5 | .99 | 0.034 |
| Sex | |||||
| Male | 65 (52.8) | 66 (53.7) | −13.3 to 11.7 | .90 | 0.016 |
| Female | 58 (47.2) | 57 (46.3) | −11.7 to 13.3 | ||
| LKN to admission, hours, median (IQR) | 7 (3.0-13) | 4.9 (2.9-10.4) | −0.2 to 2.4 | .12 | 0.005 |
| Admission NIHSS, median (IQR) | 5 (3.0-10.5) | 5 (3-11) | −1 to 1 | .88 | 0.024 |
| Baseline mRS, median (IQR) | 0 (0-1) | 0 (0-1) | −0 to 0 | .36 | 0.045 |
| Admission serum glucose level, median (IQR), mg/dL | 118 (98-148) | 113 (101-143) | −6 to 9 | .64 | 0.025 |
| Hypertension | 92 (74.8) | 96 (78) | −13.9 to 7.3 | .55 | 0.076 |
| Hyperlipidemia | 63 (51.2) | 64 (52) | −13.3 to 11.7 | .90 | 0.016 |
| Diabetes | 39 (31.7) | 34 (27.6) | −7.3 to 15.5 | .49 | 0.089 |
| Coronary disease | 17 (13.8) | 22 (17.9) | −13.2 to 5.0 | .38 | 0.111 |
| Previous myocardial infarction | 7 (5.7) | 7 (5.7) | −5.8 to 5.8 | >.99 | 0.000 |
| Atrial fibrillation | 19 (15.4) | 17 (13.8) | −7.2 to 10.5 | .72 | 0.046 |
| Heart failure | 3 (2.4) | 3 (2.4) | −3.9 to 3.9 | >.99 | 0.000 |
| Peripheral artery disease | 11 (8.9) | 11 (8.9) | −7.1 to 7.1 | >.99 | 0.000 |
| Chronic kidney disease | 12 (9.0) | 8 (6.5) | −3.6 to 10.1 | .35 | 0.119 |
| Obstructive sleep apnea | 6 (4.9) | 4 (3.3) | −3.3 to 6,6 | .52 | 0.082 |
| Previous stroke | 35 (28.5) | 31 (25.2) | −7.8 to 14.3 | .57 | 0.073 |
| Previous TIA | 6 (4.9) | 6 (4.9) | −5.4 to 5.4 | >.99 | 0.000 |
| BMI, median (IQR) | 28.4 (24.4-32.6) | 27.9 (24.1-33.3) | −1.4 to 1.9 | .73 | 0.058 |
| Malignant neoplasm | 20 (16.3) | 22 (17.9) | −11.0 to 7.8 | .74 | 0.043 |
| Current smoking | 28 (22.8) | 28 (22.8) | −10.5 to 10.5 | >.99 | 0.000 |
| Statin pretreatment | 54 (43.9) | 53 (43.1) | −11.6 to 13.2 | .90 | 0.016 |
| CCI, median (IQR) | 4 (2-5) | 3 (2-5) | −1 to 1 | .83 | 0.023 |
| CT with acute ischemic changes | 24 (19.5) | 29 (23.6) | −14.3 to 6.2 | .44 | 0.099 |
| Intravenous thrombolysis | 35 (28.5) | 40 (32.5) | −15.6 to 7.4 | .49 | 0.088 |
| Endovascular treatment | 8 (6.5) | 8 (6.5) | −6.1 to 6.1 | >.99 | 0.000 |
Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); CCI, Charlson Comorbidity Index; CT, computed tomography; LKN, last known normal; MRI; magnetic resonance imaging; mRS, modified Rankin Scale score; NIHSS, NIH Stroke Scale; SMD, standardized mean difference; TIA, transient ischemic attack.
SI conversion factor: To convert serum glucose to millimoles per liter, multiply by 0.0555.
The 95% CI for the difference between medians or percentages subtracting patients who did not undergo MRI from patients who underwent MRI.
Outcomes in the Propensity Score–Matched Cohorts
| Outcome | Group, No./total No. (%) | Relative risk (95% CI) | Difference (95% CI) | ||
|---|---|---|---|---|---|
| Patients who underwent MRI | Patients who did not undergo MRI | ||||
| Primary end point | |||||
| mRS score 3-6 at discharge | 59/123 (48.0) | 52/123 (42.3) | .44 | 1.50 (0.86 to 1.05) | 5.7 (−6.7 to 18.1) |
| Secondary end point | |||||
| Stroke or death during 1 y after discharge | 22/113 (19.5) | 14/112 (12.5) | .23 | 1.56 (0.84 to 2.89) | 6.9 (−2.6 to 16.5) |
| Death during hospitalization | 7/123 (5.7) | 4/123 (3.3) | .54 | 1.75 (0.52 to 5.83) | 2.4 (−2.7 to 7.6) |
Abbreviations: MRI, magnetic resonance imaging; mRS, modified Rankin Scale.